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INTRODUCTION
Rectal cancer is one of the most frequent malignant cancers of the modern 
days. It is an insidious disease, which is in 90% of cases detected in the 
symptomatic phase of the disease when the possibility of its healing is 
drastically reduced in relation to the asymptomatic phase (1). The basic 
treatment principle is surgical procedure, which leads to healing in 50-60% 
of the cases.
The incidence of rectal cancer is significantly different among countries. It 
is the highest in the areas where the western way of living and nutrition is 
practiced. In 100,000 people, the incidence rate of this disease in Vojvodina 
is 24.7 for men and 16.1 for women. In 2007, there were 4,909 new male 
patients  suffering  from  carcinoma  and  259  of  them  (4.9%)  had  rectal 
cancer. There were 4,462 new female patients suffering from carcinoma 
and 165 of them (3.7%) had rectal cancer. The cumulative risk represents 
the probability of a disease appearance at a certain age. Under the condi-
tion that it does not come to death as an outcome of some other cause, 
the cumulative risk of rectal cancer is 1 of 64 in the male population and 
1 of 112 in the female population (2). In our paper, a special attention was 
given to the patients with the locally advanced rectal cancer (T3-4, N1-2) 
who preoperatively received neoadjuvant chemoradiation therapy and had 
complete histological tumour regression. The aim of the combined chemo 
and radiation therapy is to improve the treatment results acting on several 
levels. The radiation therapy aims to improve the disease control and it 
functions as a radio-potentiator for the chemotherapy. Neoadjuvant chemo-
radiation therapy leads to the tumour regression, which is manifested by 
size  reduction,  down  staging  or  even  complete  tumour  disappearance. 
Tumour down staging contributes to the increase of the number of patients 
who undergo the radical surgery (3). It increases the number of sphincter-
preservation  interventions  (4),  improves  the  local  disease  control  and 
affects the survival rate (5). However, the long-term oncologic results of 
the complete histopathological tumour regression are still controversial (6).
MATERIAL AND METHODS
The  research  was  conducted  as  a  retrospective  study  at  the  Oncology 
Institute of Vojvodina, Clinic for surgical oncology. The study group con-
sisted of 223 patients who were treated for rectal cancer from 01.01.2000 
to 31.12.2004. The patients were between 32 and 82 years of age. There 
were 338 patients that underwent surgery at the Clinic during that period 
but, due to lack of data, 115 patients could not be included into the study.
The  rectal  cancer  diagnosis  and  the  stage  of  the  disease  were  deter-
mined preoperatively. Diagnostic algorithm included anamnesis, digitorectal 
examination, colonoscopy, biopsy, histopathological confirmation of adeno-
carcinoma, CT and/or MRI of small pelvis.
This study included all the patients who underwent surgery but who did not 
have stage IV of the diseases, i.e. who did not have any visible metastases 
prior to therapy.
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SUMMARY
Background: Our aim was to present the effect of the neoadjuvant chemoradiation therapy on the development of the 
complete histopathological tumour regression in patients with locally advanced rectal cancer and its influence on a five-year 
survival of these patients.
Methods: In total, 223 patients were included in the analysis; 109 patients had the locally advanced rectal cancer; 75 patients 
received the neoadjuvant chemoradiation therapy, which was later followed by surgery; 34 patients were treated with the 
surgery alone. The surgical procedure was done 6 to 8 weeks after the chemoradiation therapy and it was preceded by 
haematology and biochemical analyses. In addition, patients were examined by ultrasound and MRI imaging of liver to evalu-
ate the effects of neoadjuvant chemoradiation therapy. Accordingly, we had two patient groups: patients with the complete 
histopathological tumour regression and patients with the incomplete or no regression. We performed the statistical analysis 
of all locally advanced rectal cancer patients and determined their survival.
Results: The complete histopathological tumour regression was found in 10.7% of 75 patients who were treated with preopera-
tive chemoradiation. The down staging of the tumour appeared in 53.3% of patients. There were no stage changes in 21.3% of 
patients. The disease progressed into a more severe stage in 9.3% of patients, while the effects of the preoperative chemoradia-
tion therapy could not be determined in 5.3% of patients. The survival of patients with the complete histopathological tumour 
regression was 70% in a five-year period, while it was 40% in patients with incomplete histopathological regression.
Conclusion: The preoperative chemoradiation therapy leads to complete histopathological tumour regression and increases 
a five-year survival (70%). It also leads to the increase of the number of patients who undergo radical surgery.
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A special attention was paid to the patients who had locally advanced 
disease (109). Thirty-four of them did not receive the preoperative chemo-
radiation therapy but only underwent surgery. There were 75 patients who 
received preoperative chemoradiation therapy. 
The radiotherapy was performed on linear accelerator with the energies 
from  10  to  15  MeV.  Following  radiotherapy,  the  patients  received  the 
chemotherapy (5-FU and leucovorin) on day 1, 2, 10, 11, 20 and 21. At 
the protracted protocol, the preoperative radiation dosage was total dose 
50.4 Gy fractionally divided into the equal daily dosages of 1.8 Gy. A daily 
dosage of TD to 2 Gy was allowed to be given, but not to be exceeded, 
because of the special sensitivity of the small intestine as well as the other, 
critical organs. 
The MRI was performed and the restaging was determined 6-8 weeks after 
the chemoradiation therapy. 
Before the surgical procedure, blood and biochemical analysis were per-
formed as well as the liver ultrasound. Depending on the tumour spreading, 
either radical or palliative surgical procedure was done. The radical surgery 
implied the front lower rectal resection and the rectal amputation with the 
total mesorectal excision (TME). The palliative surgical procedures were 
the formation of the bipolar stomata or transanal tumour excision or just 
peritoneum biopsy in the case of carcinosis.
Disease stage was determined by histopathological analysis of surgical 
samples. Based on that, the two subgroups of patients were formed:
•  Patients  with  the  complete  histological  regression  (tumour  was  not 
found at the removed part of the rectum with the mesorectum) and 
•  Patients with the tumour (there was no histological regression or it was 
incomplete).
we did the statistical overall analysis of patients with the locally advanced 
rectal cancer and determined their survival. 
RESULTS
we examined 223 patients: 131 men with mean age of 63.65 years and 92 
women with mean age of 63.82 years. The ratio was 1.42:1 in favour of men.
There were 168 patients (75.3%) who underwent radical surgery and 5 
patients (24.7%) who underwent palliative surgery (Table 1).
Radical surgery was done in 75.3% of patients and palliative surgery in 
24.7% patients (Table 1). 
The  results  of  histopathological  analysis  of  surgical  samples  regarding 
tumour regarding the TNM staging of patients are shown in Table 1.
The grouping according to the stage of the disease in relation to the clini-
cal staging showed that 3.6% of patients had complete histopathological 
tumour regression; 16.1% of patients had the stage I of the disease; 22.9% 
of patients had stage II; 29.6% of patients had stage III; and 19.7% of 
patients had the stage IV. Due to the insufficient data from TNM classifica-
tion, the stage of the disease could not be determined in 8.1% of patients 
(Table 1). 
The patients who underwent surgery at the Clinic for surgical oncology 
were followed up for the evaluation of survival by the end of December 
2009. Of 223 evaluated patients, 91 patients (40.8%) are alive and 132 
patients (59.2 %) have died (Figure 1).
A five-year survival in evaluated group of patients was 50%.
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Figure 1. Survival in the evaluated group of patients
we determined the survival in relation to the type of surgery (Figure 2). 
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Figure 2. Patients’ survival in relation to the type of surgery
1 – Low anterior, 2 – Hartmann, 3 – Miles, 4 – Palliative surgery – colostomy,  
5 – Resectio rectosigmae
Figure 2 shows that the patients who underwent radical surgery (Dixon, Miles) 
have a five-year survival around 60%, which is higher than in patients who 
underwent palliative surgery and whose five-year survival rate is 20%.
Among the patients with locally advanced rectal cancer (109), 69.8% of patients 
received preoperative radiation therapy and 31.2% of patients did not (Table 1).
Among  patients  who  received  the  radiation  therapy,  85.3%  of  patients 
underwent radical surgery, while 14.7% of patients underwent palliative 
surgery. In the group of patients with the locally advanced rectal cancer that 
had no preoperative radiation therapy, 76.5% of patients underwent radical 
surgery and 23.5% of patients underwent palliative surgery (Table 1). 
we determined and compared the survival rates of patients with the locally 
advanced rectal cancer (Figure 3). we analyzed two groups: 
•  Patients who preoperatively received radiation therapy and 
•  Patients who did not preoperatively receive radiation therapy
we analysed the effect of radiation therapy, giving special attention on the occur-
rence  of  the  complete  histopathological  rectal  cancer  regression.  Seventy-five 
patients with the locally advanced rectal cancer received radiation therapy, and the 
complete histopathological tumour regression developed in 10.7% of these patients. 
From 75 patients who received the radiation therapy, 40% of patients are alive and 
60% of patients have died. From the group of patients with the complete histopatho-
logical tumour regression, 37.5% of patients are alive and 62.5% of patients have 
died. There were 67 patients with the incomplete or no tumour regression; 40.3% 5
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Table 1. Clinical characteristcs of patients with advanced rectal cancer
Patients with locally advanced cancer
with preoperative radiation therapy 75 (68.8%)
without radiation therapy 34 (31.2%)
Total 109 (100%)
Patients with preoperative radiation 
therapy (type of surgery) 
Low anterior 31 (41.3%)
Miles 32 (42.7%)
Rectosigma resection –
Hartmann 1 (1.3%)
Palliative surgery - colostomy 11 (14.7%)
Total 75 (100%)
PH finding Alive
Complete regression 3 (37.5%)
Incomplete regression 27 (40.3%)
Patients without preoperative radiation 
therapy (type of surgery)
Low anterior 12 (35.3%)
Miles 7 (20.6%)
Rectosigma resection 2 (5.9%)
Hartmann 5 (14.7%)
Palliative surgery - colostomy 8 (23.5%)
Total 34 (100%)
Died
5 (62.5%) 8 (100%)
40 (59.7%) 67 (100%)
Evaluation of radiation therapy effects No (%)
Complete pathohistological tumour 
regression
8 (10.7%)
Down-staging  40 (53.3%)
without changes 16 (21.3%)
Progression 7 (9.3%)
Undefined effect 4 (5.3%)
Total 75 (100%)
Gender  No of patients / %
Male 131
Female 92
TNM stage No of patients / %
Stage 0 8 (3.6%)
Stage 1 36 (16.1%)
Stage 2 51 (22.9%)
Stage 3 66 (29.6%)
Stage 4 44 (19.7%)
Undetermined stage 18 (8.1%)
Total 223 (100%)
Type of surgery
Miles 58 (26.0%)
Low anterior 91 (40.8%)
Hartmann 11 (4.9%)
Recto sigma resection 8 (3.6%)
Palliative surgery - colostomy 55 (24.7%)
Total 223 (100%)
of them are still alive, while 59.7% of them have died. Test of statistical significance 
did not show any significant statistical difference (p>0.05) (Table 1).
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Figure 3. Patient survival according to preoperative radiation
Of 75 examined patients, 40% of patients are still alive, while 60% of 
patients have died. Of 8 patients (stage 0), 37.5% of patients are alive 
and 62.5% of patients have died; of 8 patients (stage I), 62.5% of patients 
are alive and 37.5% patients have died; of 16 patients (stage II), 50.0% 
are alive and 50.0% have died; of 32 (stage III patients), 40.6% are alive 
and 59.4% patients have died; of 7 patients (stage IV), 14.3% of patients 
are alive, while 85.7% of them have died. Because of the incomplete 
data from TNM classification, 4 patients were not included into this clas-
sification.
The evaluation of radiation therapy effects showed response in 64% of 
patients, 21.3% of patients had unchanged findings, and 9.3% of patients 
had disease progression (Table 1). we could not estimate the effect of the 
preoperative radiation therapy in 5.3% of patients due to insufficient data 
from the TNM classification.
we determined and compared the survival for two groups of patients 
with the locally advanced rectal cancer who were previously treated 
with the chemoradiation therapy. In patients with the complete histo-
pathological tumour regression a five-year survival was 70% and in 
patients  without  the  complete  histopathological  tumour  regression  it 
was 40% (Figure 4). 
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Figure 4. Survival in relation to histopathological tumour regression
1 – Without complete histological regression
2 – With complete histological regression6
Articles
www.onk.ns.ac.rs/Archive  Vol 18, No. 1-2, July 2010
80 60 40 20 0
Survival by months
1.0
0.8
0.6
0.4
0.2
0.0
C
u
m
 
S
u
r
v
i
v
a
l
0
4
1
3
2
Figure 5. Patient survival according to stage of the disease (Stage 0-4)
we used the Kaplan-Maier method to present the survival in patients who 
were  treated  with  the  preoperative  radiation  therapy  in  relation  to  the 
clinical stage of the disease. we found that a five-year survival in patients 
with S0 of disease was 70%, 65% in patients with S1, 55% in patients with 
S2, 45% in patients with S3 stage, and 15% in patients with S4 of disease 
(patients with distant metastases) (Figure 5).
One of the indicators of the combined therapy success was the presence of the 
local recurrence. In our study group, 8 patients from 64 patients that underwent 
radical  surgery  had  the  basic  disease  recurrence. After  rectal  resection,  3 
patients developed the local recurrence and it developed in 5 patients that under-
went rectal amputation. From these 8 patients, there were 5 men and 3 women. 
In 4 patients, the therapy for the local recurrence was the radiation therapy and 
the recurrence was surgically removed in 2 patients. The combination of surgery 
and radiation therapy was performed in one case. Nothing was done in one case.
DISCUSSION
Modern treatment of the rectal cancer is based on the determination of the 
stage of the disease. It gives insight in the prognostic factors as well as in 
the choice of therapy. For the classification of the stage of the disease, the 
TNM classification is used. It is clear that its precise determination is nec-
essary. The chemoradiation therapy is used in the treatment of the locally 
advanced rectal cancer (T3-4 N1-2). The numerous studies have shown that its 
preoperative use contributes to the tumour regression, which can be partial 
or complete. It also reduces the frequency of recurrence and increases the 
use of the radical surgery, especially sphincter-preservation procedures. It 
must not be forgotten that these patients have a larger number of postop-
erative complications in relation to the patients who did not receive this 
preoperative therapy. Patients with the complete histopathological tumour 
regression have a five-year survival of 70%, while the patients without the 
complete histopathological tumour regression have a significantly lower 
five-year survival of 40%.
Julio Garcia-Aguilar and associates published a paper, which included 168 
patients that received preoperative radiation therapy. They reported that 
down staging was manifested in 58% of patients, including 13% of patients 
with the complete histopathological tumour regression. In this study, a five-
year survival was 95.2% in patients with the complete histopathological 
tumour regression, while it was 55.4% in patients without the complete 
histopathological regression (7).
Francesco Stipa and associates published a paper, which analyzed 476 
patients with the locally advanced rectal cancer who were treated with the 
preoperative radiation therapy. The complete histopathological regression 
developed in 12.6% of patients, while there was no down staging in 29.5% 
of patients. A five-year survival in patients with the complete histological 
tumour regression was 90%. The patients without the tumour down staging 
had a five-year survival of 68% (8).
If we compare the results of our study, it can be seen that the complete 
histopathological  regression  manifested  in  a  small  percent  of  patients 
(10.7%), while the survival of patients with the complete histopathological 
tumour regression was 70%, which was significantly lower in relation to the 
above-mentioned studies. 
In their study, Hak-Mien quah and associates presented the disease recur-
rence. Of 331 patients that were analyzed in the study, 22% developed 
recurrence.  They  analyzed  the  survival  in  relation  to  the  stage  of  the 
disease. The survival of patients with the stage S0 (the complete histopatho-
logical regression) was 90%; the patients with the stage S1 had the survival 
of 85%; the survival of patients with the stage S2 was 65% and it was 45% 
in patients with the stage S3 (9).
In our study the local recurrence developed in 12.5% of patients in the 
group of 64 patients that underwent radical surgery. Patients with the S0 
stage had the survival of 70%. It was 65% in patients with the S1 stage of 
the disease, while the survival of the patients with the S2 stage was 55%. In 
patients with the S3 stage of the disease, the survival was 45%. A five-year 
survival was 15% in patients with the S4 stage (patients with the distant 
metastases). 
For the time being, the study does not explain the mechanism of the complete 
histopathological tumour regression after the preoperative chemoradiation 
therapy that develops in some patients (it happens in 10%-30%). However, 
it can be noticed that these patients have a better survival in relation to the 
patients with the incomplete or no histopathological tumour regression.
The molecular studies try to discover the factors responsible for the develop-
ment of the complete histopathological regression in some patients. This 
discovery  would  make  the  therapeutic  treatment  more  efficient.  Several 
studies have proven that the discovery of certain molecular biomarkers (PCNA 
index, p21 expression and p53 immunostaging) in the pre-radiation biopsy 
can predict the response of a tumour to the chemoradiation therapy (10).
we concluded that the preoperative chemoradiation therapy (neoadjuvant 
therapy) leads to:
•  The complete histopathological tumour regression thus increasing a 
five-year survival (70%).
•  The increase of the number of patients with radical surgery (85%) 
compared to the patients without preoperative radiation therapy (75%). 7
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•  The increase of the number of the sphincter-preservation interventions 
in relation to the amputation procedures. The previous relation was 
70% to 30%, and now it is 50% to 50%.
•  The reduction of the local recurrence from previous 39% to current 12.5%
•  Because of the adoption of the TME and the introduction of the chemoradia-
tion therapy, the percentage of the patients that underwent radical surgery 
was 80% in 2005. In 1985 it was 50% and in 1995, 61% (historical data).
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